SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytokine1 who wrote (3279)11/1/1997 12:21:00 AM
From: chirodoc  Read Replies (1) of 9719
 
i was wondering why fuse was doing so poorly. i thought it was just because i decided to buy some. here is an article that you may have already seen.......but it describes some company info........anyone have any feedback on this company?

Fuisz sees more than $25 mln revs from buys

CHANTILLY, Va., Oct 30 (Reuters) - Fuisz Technologies Ltd Thursday said revenues from completed acquisitions in 1997 will contribute more than $25 million in total annual revenues.

Earlier, the company reported total operating revenues for the third quarter of $2.9 million from $867,000 a year ago. Fuisz reported a net loss for the quarter, before one-time charges, of $6.5 million, or $0.31 per share due to its previously announced plan to speed up its core strategy to develop, make, and commercialize its own products by heavily investing in research and development, and expand its infrastructure. A year ago, it posted a net loss of $2.2 million or $0.11 per share.

''The operating strategies we have pursued over the last three quarters have positioned the company to begin fulfilling its vision of becoming a full service pharmaceutical and drug delivery company,'' said Ken McVey, president and chief executive officer of Fuisz.

''Toward this end, I am very pleased not only that we have been able to advance our technologies, for example, by development of CEFORM RA (rapid acting) ibuprofen microspheres, but also that we have been able to identify important connections into several of the major international markets as a result of our recent international acquisitions of Istoria Farmaceutici in Italy, Clonmel Healthcare in Ireland, and Laboratoires Murat in France.''
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext